EHRA 2023: Late-Breaking Science Video Collection

Published: 18 April 2023

  • Views:

    Views Icon 2050

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice. 

More from this programme

Part 1

Expert Interviews

7 sessions
POTTER: Oesophageal Fistulae in Catheter Ablation Patients Watch now
AdaptResponse: AdaptivCRT® Algorithm in Synchronized LV Pacing Watch now
MANIFEST-PF: Real-world Experience of PFA in Commercial Practice Watch now
ANTWOORD II: LVEF Recovery After Atrial Fibrillation Ablation in Heart Failure Patients Watch now
TEMPO-HCM: Extended ECG Monitoring in HCM Watch now
Conformable PVI Catheter for Pulmonary Vein Isolation Watch now
BRUGADA Randomized: Epidcardial Ablation to Prevent Sudden Death Watch now

Part 2

Featured Highlights

In these concise overviews, selected faculty provide their thoughts on the most impactful trials from EHRA 2023. 

2 sessions
5 Trials That Will Change Your Practice With Dr Sohaib Watch now
4 Trials That Will Change Your Practice With Dr Di Biase Watch now

Part 3

Behind the Heart

Watch our Behind the Heart series to learn more about the personal perspectives of the investigators behind top trials in cardiovascular science.

5 sessions
Dr Bergonti: Pulsed-Field Ablation & Reasons to Research Watch now
Dr Bruce Wilkoff: Therapy Morbidity and Advice to Young Researchers Watch now
Dr Carlo Pappone: Advice to Early-Career Electrophysiologists Watch now
Dr Juan Caro Codon: Building a Team For Success Watch now
Dr Vivek Reddy: Pulsed-Field Ablation’s Transformative Impact and Advice For Young Researchers Watch now

About the episode

EHRA 23 - Dr Marco Bergonti (Istituto Cardiocentro Ticino, CH) to discuss the key takeaways from the ANTWOORD II Trial. 

In this study, 605 heart failure patients undergoing atrial fibrillation ablation were enrolled to receive an ANTWERP Score, which aimed to predict LVEF recovery. 70% of patients were categorised as 'responders', patients identified as those who could benefit the most from AF ablation. 

Results suggest that responders to the study achieved 10 times less deaths and heart transplantations, 10 times less heart failure hospitalisations and 8 times more positive left ventricular remodeling. 

Questions:

  1. Can you provide a brief overview of the ANTWOORD I trial and explain the research question that ANTWOORD II aims to address?
  2. Could you elaborate on the ANTWERP scoring system and how it is used in the study?
  3. Can you describe the study design, entry criteria, and patient population in detail?
  4. What were the main findings of the study and what conclusions can be drawn from them?
  5. What are the clinical implications of the study?
  6. What are some limitations of the study that should be considered?
  7. What are the next steps?

Recorded from EHRA 2023, Barcelona.

Faculty Biographies

Marco Bergonti

View full profile

Comments

You must be to comment. If you are not registered, you can register here.